Dendritic Cell (DC)-based vaccine is a tumor immunotherapy approach with great potential, and improving the efficacy is an urgent problem to be solved. RIPK1 is an important regulator of inflammation and cell death, and may play a significant role in the tumor immune function of DCs. Our study found that DC-specific knockout of Ripk1 can inhibit tumor growth in mice by increasing DC immune infiltration and strengthening the interactions with cytotoxic T cells in the tumor microenvironment. The e